{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:13:33Z","timestamp":1791929613480,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","pediatric.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Clinics of North America"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.pcl.2014.09.018","type":"journal-article","created":{"date-parts":[[2014,10,18]],"date-time":"2014-10-18T10:48:16Z","timestamp":1413629296000},"page":"301-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Remaining Challenges in Childhood Cancer and Newer Targeted Therapeutics"],"prefix":"10.1016","volume":"62","author":[{"given":"Malcolm A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory H.","family":"Reaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.pcl.2014.09.018_bib1","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.pcl.2014.09.018_bib2","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/pbc.25036","article-title":"Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer","volume":"61","author":"Smith","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.pcl.2014.09.018_bib3","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.pcl.2014.09.018_bib4","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1172\/JCI64400","article-title":"A\u00a0remarkably simple genome underlies highly malignant pediatric rhabdoid cancers","volume":"122","author":"Lee","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.018_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrg3673","article-title":"Every amino acid matters: essential contributions of histone variants to mammalian development and disease","volume":"15","author":"Maze","year":"2014","journal-title":"Nat Rev Genet"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.018_bib6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","article-title":"Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation","volume":"18","author":"Wilson","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.pcl.2014.09.018_bib7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1172\/JCI71605","article-title":"Cancer epigenetics drug discovery and development: the challenge of hitting the mark","volume":"124","author":"Campbell","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"19","key":"10.1016\/j.pcl.2014.09.018_bib8","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"2","key":"10.1016\/j.pcl.2014.09.018_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","article-title":"hDOT1L links histone methylation to leukemogenesis","volume":"121","author":"Okada","year":"2005","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pcl.2014.09.018_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L","volume":"20","author":"Bernt","year":"2011","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.pcl.2014.09.018_bib11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pcl.2014.09.018_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.18632\/oncotarget.1495","article-title":"Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing sarcoma","volume":"5","author":"Hong","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.018_bib13","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.pcl.2014.09.018_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.seminhematol.2014.05.007","article-title":"The B-cell receptor pathway: a critical component of healthy and malignant immune biology","volume":"51","author":"Zhong","year":"2014","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.pcl.2014.09.018_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.pcl.2014.09.018_bib16","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","article-title":"Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome","volume":"116","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pcl.2014.09.018_bib17","unstructured":"Roberts KG, Li Y, Payne-Turner D, et\u00a0al. The genetic landscape of Ph-like acute lymphoblastic leukemia. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research. San Diego (CA); Philadelphia: AACR; 2014:[abstract: #3083]."},{"issue":"3","key":"10.1016\/j.pcl.2014.09.018_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccr.2014.02.004","article-title":"Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition","volume":"25","author":"Kool","year":"2014","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.pcl.2014.09.018_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bpa.12023","article-title":"Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail","volume":"23","author":"Fontebasso","year":"2013","journal-title":"Brain Pathol"},{"key":"10.1016\/j.pcl.2014.09.018_bib20","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.14694\/EdBook_AM.2014.34.e436","article-title":"Targeting BRAF in pediatric brain tumors","author":"Kieran","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"10.1016\/j.pcl.2014.09.018_bib21","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved for BRAF-mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"10.1016\/j.pcl.2014.09.018_bib22","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pcl.2014.09.018_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fonc.2014.00063","article-title":"Blinatumomab, a bi-specific anti-CD19\/CD3 BiTE((R)) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications","volume":"4","author":"Hoffman","year":"2014","journal-title":"Front Oncol"},{"issue":"17","key":"10.1016\/j.pcl.2014.09.018_bib24","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pcl.2014.09.018_bib25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/pbc.22576","article-title":"Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program","volume":"55","author":"Kolb","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.pcl.2014.09.018_bib26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jnci\/90.7.505","article-title":"Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts","volume":"90","author":"Zamboni","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.pcl.2014.09.018_bib27","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1200\/JCO.2005.02.097","article-title":"Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach","volume":"23","author":"Santana","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.pcl.2014.09.018_bib28","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1158\/1078-0432.CCR-12-0738","article-title":"Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response","volume":"18","author":"Wong","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.pcl.2014.09.018_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/jpet.111.188870","article-title":"Pharmacokinetic\/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models","volume":"340","author":"Yamazaki","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"12 Pt 1","key":"10.1016\/j.pcl.2014.09.018_bib30","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","article-title":"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Christensen","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"10.1016\/j.pcl.2014.09.018_bib31","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.pcl.2014.09.018_bib32","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/pbc.21368","article-title":"Initial testing of dasatinib by the pediatric preclinical testing program","volume":"50","author":"Kolb","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.pcl.2014.09.018_bib33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.leu.2404508","article-title":"Antitumor activity of sorafenib in FLT3-driven leukemic cells","volume":"21","author":"Auclair","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.pcl.2014.09.018_bib34","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.leukres.2010.10.025","article-title":"Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3\/ITD+) acute myeloid leukemia after allogenic stem cell transplantation","volume":"35","author":"Sora","year":"2011","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.pcl.2014.09.018_bib35","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/j.leukres.2010.04.011","article-title":"Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report","volume":"34","author":"Winkler","year":"2010","journal-title":"Leuk Res"},{"issue":"Suppl","key":"10.1016\/j.pcl.2014.09.018_bib36","first-page":"5s","article-title":"A\u00a0phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: a Pediatric Brain Tumor Consortium report","volume":"32","author":"Banerjee","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pcl.2014.09.018_bib37","series-title":"National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease","year":"2011"},{"issue":"31","key":"10.1016\/j.pcl.2014.09.018_bib38","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.pcl.2014.09.018_bib39","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study","volume":"14","author":"Mosse","year":"2013","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.pcl.2014.09.018_bib40","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.pcl.2014.09.018_bib41","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1056\/NEJMoa0808455","article-title":"Antivenom for critically ill children with neurotoxicity from scorpion stings","volume":"360","author":"Boyer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"28","key":"10.1016\/j.pcl.2014.09.018_bib42","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"66","key":"10.1016\/j.pcl.2014.09.018_bib43","doi-asserted-by":"crossref","first-page":"66cm1","DOI":"10.1126\/scitranslmed.3001707","article-title":"\u201cCreating hope\u201d and other incentives for drug development for children","volume":"3","author":"Connor","year":"2011","journal-title":"Sci Transl Med"}],"container-title":["Pediatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395514001977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031395514001977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T12:20:55Z","timestamp":1538137255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031395514001977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0031395514001977"],"URL":"https:\/\/doi.org\/10.1016\/j.pcl.2014.09.018","relation":{},"ISSN":["0031-3955"],"issn-type":[{"value":"0031-3955","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remaining Challenges in Childhood Cancer and Newer Targeted Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Pediatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcl.2014.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}